Letters to the editor (multiple letters)

Clinical Therapeutics

Volumn 23, Issue 2, 2001, Pages 307-308

  Glazer, N Bradly ^a   Cheatham, Wayman Wendell ^b   Malinowski, Jennifer M ^c   Bolesta, Scott ^d  

^a Scientific Communication   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c WILKES UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; THIAZOLE DERIVATIVE;

DIABETES MELLITUS; DRUG EFFECT; DRUG INDUCED DISEASE; HUMAN; LETTER; LIPOPROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; NOTE;

HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0035260047     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80013-8     Document Type: Letter

References (3)

1. JM Malinowski S Bolesta Rosiglitazone in the treatment of type 2 diabetes mellitus: A critical review Clin Ther. 22 2000 1151 1168
2. ® [package insert] 1999 Takeda Pharmaceuticals America, Inc Lincolnshire, Ill
3. ® [package insert] 2000 SmithKline Beecham Pharmaceuticals Philadelphia, Pa